BRRGF:OTC-BerGenBio ASA (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 3.50

Change

0.00 (0.00)%

Market Cap

USD 0.31B

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

BerGenBio ASA, a clinical-stage biopharmaceutical company, engages in the developing drugs to treat immune evasive, drug resistant, and metastatic cancers. Its lead candidate is Bemcentinib, a bio-available small molecule AXL inhibitor, which is in Phase II clinical development in major cancer indications and COVID-19. The company's Phase II clinical trial program focuses on treatment of non-small cell lung cancer, acute myeloid leukaemia, and myelodysplastic syndrome, as well as COVID-19. In addition, it is developing tilvestamab, an anti-AXL antibody that is in Phase I clinical trial. BerGenBio ASA has a collaboration agreement with Merck & Co. for clinical trials. The company was incorporated in 2007 and is headquartered in Bergen, Norway.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

-3.97 (-3.88%)

USD231.51B 33.96 3.79
CMXHF CSL Limited

+4.26 (+1.89%)

USD103.66B 43.17 29.42
CSLLY CSL Limited

+0.81 (+0.72%)

USD103.52B 43.18 29.42
WXIBF WuXi Biologics (Cayman) Inc

-0.54 (-3.41%)

USD67.02B 159.60 28.65
WXXWY WuXi Biologics (Cayman) Inc

+0.60 (+1.92%)

USD66.53B 157.93 28.65
GNMSF Genmab A/S

+4.50 (+1.00%)

USD29.51B 75.21 8.17
UCBJY UCB SA

-0.79 (-1.39%)

USD20.92B 19.45 14.67
UCBJF UCB SA

N/A

USD20.91B 18.63 14.67
SBHMY Sino Biopharmaceutical Limited

N/A

USD16.22B 10.75 2.15
SBMFF Sino Biopharmaceutical Limited

N/A

USD15.66B 10.39 2.15

ETFs Containing BRRGF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.17% 44% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.17% 44% F 30% F
Trailing 12 Months  
Capital Gain -7.89% 42% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.89% 41% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 24.18% 46% F 61% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.18% 45% F 59% F
Risk Return Profile  
Volatility (Standard Deviation) 80.26% 53% F 38% F
Risk Adjusted Return 30.13% 53% F 50% F
Market Capitalization 0.31B 79% C+ 59% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 5.22 54% F 24% F
Price / Cash Flow Ratio -1.32 40% F 65% D
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -47.79% 53% F 18% F
Return on Invested Capital -58.67% 26% F 12% F
Return on Assets -27.63% 58% F 21% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.52 25% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector